Brain Injury Derived Neurotrophic Peptide

Brain Injury Derived Neurotrophic Peptide (CPC catalog code NEUP-016) is a synthetic neuropeptide receptor ligand in the neuropeptides category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.

Published and internal research programs use Brain Injury Derived Neurotrophic Peptide as a reference standard in neuropeptides workflows — for example, gpcr receptor-binding and functional profiling and behavioral pharmacology (rodent models). Human clinical evidence is not established.

No. Brain Injury Derived Neurotrophic Peptide is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.

In a neuropeptides workflow, Brain Injury Derived Neurotrophic Peptide is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. Radioligand binding, cAMP HTRF, calcium mobilization, and in vivo behavior assays.

Store lyophilized at −20 °C. Reconstitute in sterile 0.1% BSA/PBS to reduce adsorption. Follow your institution's standard operating procedures for handling synthetic peptides.

This kindr reference page mirrors CPC Scientific's catalog metadata for NEUP-016. The upstream reference sheet — including sequence, purity, MW, and application notes where published — is linked from the buy panel. All orders placed on kindr Peptides ship internationally under research-use terms only.

Research-grade peptides in the CPC catalog are synthesized by solid-phase peptide synthesis (SPPS), purified by preparative RP-HPLC, and characterized by analytical HPLC and mass spectrometry. Typical purity is ≥95%; certificate of analysis is available on request.